압타바이오
293780KOSDAQ자연과학 및 공학 연구개발업56.4 / 100
Reference Date: 2026-07-24
Company InformationBased on 2025 Annual Report
Business Overview
AptaBio is a specialized pharmaceutical company developing innovative drugs based on three platform technologies: oxidative stress modulation, CAF Modulation, and aptamer-drug conjugate (Apta-DC). The company focuses on drug pipeline development, including eight therapeutic candidates, and expanded into health functional food ODM and pet care businesses through its newly established New Business Division in 2023. Key revenue streams include technology fees, reagent sales, and product sales from new business segments.
Number of Employees
45people
Average Salary
57.7M KRW
Score Calculation Basis
Detailed Financial Score
Higher than industry avg (caution)
In line with industry avg
In line with industry avg
Avg ▲473.9% (2-year basis)
Avg ▲0.4% (2-year basis)
Avg ROE -34.8% (declining, 3yr)
Detailed News Sentiment
- Positive압타바이오, '급성 신손상 신약' 연내 성패 갈린다
압타바이오의 급성 신손상 신약 임상 2상 완료로 연내 성공 가능성이 높아져 긍정적인 시장 반응 예상.
- Positive압타바이오, ‘아이수지낙시브’ 글로벌 2상 추적관찰 완료…하반기 .....
압타바이오의 혁신 치료제 '아이수지낙시브'가 글로벌 임상 2상 추적관찰을 성공적으로 완료하며 긍정적인 신호를 보냈다.
- Positive압타바이오, '혈액암 신약' 3대 암학회 연속 채택
압타바이오의 혈액암 치료제 후보물질이 주요 암학회에서 연속 채택되어 임상 진입 가능성이 높아졌다.
Detailed Momentum
Near 52w low (14%, downtrend)
1m +10.95% (rising)
Volume flat